Related Experiment Video
Updated: Jun 14, 2025
05:06
Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
1.6K
Peripheral neuropathy: from guidelines to clinical practise
Berit Jordan1,2,3, Franziska Jahn4, Karin Jordan1,5
1Department of Hematology, Oncology and Palliative Medicine, Ernst von Bergmann Hospital Potsdam, Potsdam.
Current Opinion in Oncology
|January 27, 2025
Summary
Chemotherapy-induced peripheral neuropathy (CIPN) lacks effective prevention. Emerging biomarkers like serum neurofilaments and promising interventions such as physical exercise may improve patient care.
Area of Science:
- Oncology
- Neurology
- Pharmacology
Background:
- Chemotherapy-induced peripheral neuropathy (CIPN) is a significant treatment complication.
- Current objective grading and prevention strategies for CIPN are lacking.
- Subjective assessments hinder reproducible CIPN evaluation.
Purpose of the Study:
- To review recent advancements in understanding and managing CIPN.
- To explore potential biomarkers for early detection of axonal damage.
- To evaluate promising therapeutic and preventive strategies for CIPN.
Main Methods:
- Review of preclinical and clinical studies on CIPN.
- Analysis of emerging biomarkers for axonal damage.
- Evaluation of therapeutic interventions including physical exercise and pharmacotherapy.
Main Results:
- Serum neurofilaments show potential as biomarkers for axonal damage in CIPN.
- SARM1 pathway is implicated in toxic neuropathy.
- Physical exercise, sensorimotor training, and whole-body vibration show promise for functional recovery.
- Gabapentinoids demonstrated no significant benefit in a systematic review.
Conclusions:
- Further research is needed for biomarker quantification before CIPN symptom onset.
- Biomarker development can aid in early axonal degeneration detection.
- Patient-centered care integrating new findings is crucial for managing CIPN.
